News

Zydelig was approved by the U.S. Food and Drug Administration on July 23, 2014 for the treatment of three B-cell blood cancers. "We are pleased to partner with

Apart from Norway, ILUVIEN is now approved for marketing in Austria, France, Germany, Italy, Portugal, Spain and the UK, and is commercially available in the UK and Germany.

As part of the deal, Lion has licensed from Moffitt the rights to develop and commercialize new technologies to improve TIL production from melanoma, which may be applicable

The CHMP recommendation of OZURDEX (dexamethasone 700mcg intravitreal implant in applicator) is for DME patients who are pseudophakic (have an artificial lens implant), or who are considered insufficiently

The Phase II trial is designed to assess the safety, tolerability and efficacy of RTA 408 Lotion versus vehicle for the prevention and treatment of radiation dermatitis in

According to the companies, the Phase III trial called RESILIENCE failed to meet its primary endpoint of improving progression-free survival (PFS). In the randomized, double-blind, placebo-controlled trial, the

According to Aparna Krishnan, MS, GlobalData’s Analyst, and Joshua Owide, GlobalData’s Director of Healthcare Industry Dynamics, the rationale for the deal consisted of a mix of portfolio diversification,

The company announces that it has achieved effective knock-down of the expression of a target gene in the brain in a sequence-specific manner. Independent analysis of brain tissue

DIL is a world leader in developing and providing the finest products in food technology today. Under the terms of the agreement, DIL will manufacture and supply Fortetropin